GGPS1 Mutation and Atypical Femoral Fractures with Bisphosphonates

TO THE EDITOR: Atypical femoral fractures have been associated with long-term bisphosphonate treatment. However, the underlying mechanisms remain obscure. We studied three sisters who had atypical femoral fractures after receiving various oral bisphosphonates for 6 years. Two of the sisters had a single fracture (at the ages of 64 and 73 years), and one had bilateral fractures (one at the age of 60 years and the other at the age of 61 years). Given the low incidence of atypical femoral fractures in the general population (5.9 per 10,000 person-years), we hypothesized that these sisters might have an underlying genetic background that contributed to these fractures.

We performed whole-exome sequencing to detect possible shared genetic variants involved in their apparent increased risk. In addition, we performed whole-exome sequencing in three unrelated patients with atypical femoral fractures who each had received bisphosphonates for more than 5 years. We prioritized rare nonsynonymous mutations in the variant filtering, and only mutations that were shared among the three sisters were considered. No mutation was found to be homozygous or in any gene containing mutations in both chromosomes (compound heterozygous). Assuming that a dominant model was involved, we detected 37 rare mutations (in 34 genes), among them a novel p.Asp188Tyr substitution in the enzyme geranylgeranyl pyrophosphate synthase (GGPS1), which is a site of inhibition by bisphosphonates in the mevalonate pathway. The variant that is located in the genomic position g.235505746G→T on chromosome 1 (GRCh37/hg19) in GGPS1 had the best conservation score and was not described in any of the available databases. This variant would be expected to severely impair the enzyme activity (Fig. 1). Furthermore, the gene encoding cytochrome P-450 family 1 subfamily A member 1 (CYP1A1), which is involved in steroid metabolism, was also mutated in all three sisters and in one of the unrelated patients, which suggests that it could be another potential susceptibility gene for bisphosphonate-related atypical femoral fractures. An additional mutation in the gene encoding mevalonate diphosphate decarboxylase (MVD) was detected in one unrelated patient.

Pathway analysis of the mutated genes showed enrichment of the isoprenoid biosynthetic pathway (GO:0008299), which includes GGPS1, CYP1A1, and MVD (P<0.001). We speculate that other variants that have been identified might also be involved in susceptibility to bisphosphonate-related atypical femoral fractures. Such variants include missense changes in the gene encoding fibronectin 1 (FN1) and in the genes encoding synapse defective Rho GTPase homolog 2 (SYDE2) and neuronal guanine nucleotide exchange factor (Ngef); the latter two proteins are regulators of small GTPases. We speculate that our results may support a model in which accumulation of susceptibility variants (including some in rele-

---

THIS WEEK’S LETTERS

1794 GGPS1 Mutation and Atypical Femoral Fractures with Bisphosphonates
1795 Crizanlizumab in Sickle Cell Disease
1797 Approach to Fever in the Returning Traveler
e37 Bilateral versus Single Internal-Thoracic-Artery Grafts
e38 A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
vant genes, notably GGPS1 may lead to a possible genetic component of predisposition to atypical femoral fractures.

Neus Roca-Ayats, M.Sc.
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER)
Barcelona, Spain

Susana Balcells, Ph.D.
University of Barcelona
Barcelona, Spain

Natàlia Garcia-Giralt, Ph.D.
Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES)
Barcelona, Spain

Maite Falcó-Mascaró, M.Sc.
Núria Martínez-Gil, M.Sc.
Josep F. Abril, Ph.D.
University of Barcelona
Barcelona, Spain

Roser Urreizti, Ph.D.
CIBERER
Barcelona, Spain

Joaquín Dopazo, Ph.D.
CIBERER
Valencia, Spain

José M. Quesada-Gómez, M.D., Ph.D.
CIBERER
Cordoba, Spain

Xavier Nogués, M.D., Ph.D.
CIBERFES
Barcelona, Spain

Leonardo Mellibovsky, M.D., Ph.D.
Institut Hospital del Mar d’Investigacions Mèdiques
Barcelona, Spain

Daniel Prieto-Alhambra, M.D., Ph.D.
James E. Dunford, Ph.D.
Muhammad K. Javaid, M.B., B.S., Ph.D.
University of Oxford
Oxford, United Kingdom

R. Graham Russell, M.D., Ph.D.
University of Sheffield
Sheffield, United Kingdom

Daniel Grinberg, Ph.D.
CIBERER
Barcelona, Spain

Adolfo Díez-Pérez, M.D., Ph.D.
CIBERFES
Barcelona, Spain

adiez@parcdesalutmar.cat

Supported by grants (SAF2011-25431 and SAF2014-56562R) from the Spanish Ministry of Economy and Competitiveness, grants (2009SGR971 and 2014SGR932) from the Catalan government, a grant (FP13/02066) from the Spanish Ministry of Education, Culture and Sports, a grant (U720) from CIBERER, and a grant (FIS PI13/00444) to CIBERFES from Instituto Carlos III, and by FEDER funds.

Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.


DOI: 10.1056/NEJMc1612804